Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 November 2024
Avapritinib for treating advanced systemic mastocytosis (TA1012)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 November 2024
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 October 2024
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 September 2024
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2024
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 January 2024
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal) (TA938)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 December 2023
Ruxolitinib for treating polycythaemia vera (TA921)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023
Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 February 2023
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 December 2022
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal) (TA845)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2022
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) (TA846)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2022
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) (TA843)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2022
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) (TA844)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 November 2022
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal) (TA838)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 November 2022
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 October 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 January 2022Published: 4 September 2019
Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 October 2021
Midostaurin for treating advanced systemic mastocytosis (TA728)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 September 2021
Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 June 2021
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 May 2021
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 May 2021
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2020
Patiromer for treating hyperkalaemia (TA623)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 February 2020
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 January 2020
Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 October 2019
Eltrombopag for treating chronic immune thrombocytopenia (TA293)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2018Published: 24 July 2013
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 26 October 2018Published: 27 April 2011
Tocilizumab for treating giant cell arteritis (TA518)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 April 2018
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2016
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 November 2014
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 March 2011
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 22 January 2025
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 February 2025
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 June 2025
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 16 July 2025
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 August 2025
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Canakinumab for untreated Schnitzler syndrome [ID4063]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria TS ID 10250Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 TS ID 10766Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Exagamglogene autotemcel for treating sickle cell disease [ID4016]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over TS ID 10642Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome TS ID 11820Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Upadacitinib for treating giant cell arteritis [ID6299]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over TS ID 11891Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over ID6457Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC